Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Nom du journal : Br J Haematol
Année : 2023
Volume : 201
Page de départ : 1116-1124
